Quantus

Xcell Therapeutics

A373110 · KOSDAQ
₩1,089-0.55%
2026-08-03 close

Xcell Therapeutics — what's the grade? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 295 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -11.06
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-11.06
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
-15.08%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

1/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score1/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -362%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 278 of 290, share 0%.

278 / 2900%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6엑셀세라퓨틱스0%

Concentration

DistributedCR3 16.6%
HHI 201290 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
269

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-482.2%
Interest coverage
-27.8x
Return on equity (ROE)
-104.6%

Operating margin −5pp

Operating loss
Interest coverageBase -27.8x adverse case -28.1x
Return on equity (ROE)Base -104.6% adverse case -107%

Revenue −15%

Interest coverage risk
Interest coverageBase -27.8x adverse case -23.7x
Return on equity (ROE)Base -104.6% adverse case -90.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -27.8x adverse case -19x
Return on equity (ROE)Base -104.6% adverse case -107.6%

Interest coverage limit

Already below the limit by 499.5pp

Interest coverage limit at an operating margin of 17.3%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-05-15

Suppliers disclosed by the company in its 2026-05-15 annual report.

Suppliers without disclosed amount

GMPCellCorVTM

Financials at a glance

Xcell Therapeutics's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 이의일18.75%2026-04-01 · 증감 -0.79%p

Connections

AI-extracted related companies · for reference

Competitors
Thermo Fisher ScientificSartoriusDanaherMerck KGaALonza
Same theme
세포·유전자치료제바이오의약품 CDMO
🔗 See in the full market map →

Recent filings

Xcell Therapeutics's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy